Dolat Capital: Gland Pharma IPO - B2B Play On Injectables 
An employee examines vials of injection solution inside a lab Photographer (Qilai Shen/Bloomberg)

Dolat Capital: Gland Pharma IPO - B2B Play On Injectables 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Established in 1978 in Hyderabad as a liquid parenteral company, Gland pharma covers the entire value chain of injectables such as own and contractual development, dossier preparation and filing, tech transfer and manufacturing across a range of delivery systems.

The company has presence in sterile injectables, oncology and ophthalmic, and focus on complex injectables, NCE-1s, first to-file products.

The company’s primary business to business model covers IP-led, technology transfer and contract manufacturing models, complemented by a business to consumer model in its home market of India leveraging its brand strength and sales network ably supported by regulatory capabilities.

Click on the attachment to read the full report:

Dolat Capital Gland Pharma IPO Note.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.